Handelsavisen
prelaunch
Companies Healthcare PYFA.JK
PY
PYFA.JK IDX (Jakarta) Pharmaceuticals

Pyridam Farma Tbk PT

$242,00
Open in Charts → Attach watcher ⌖
IDR
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
2,72T IDR
P/E
EV / Rev
Div yield
0,00 %
Op margin
-7,9 %
ROE
-49,5 %
Net margin
-13,8 %
Debt / equity
6,31
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Pyridam Farma Tbk PT is an Indonesian pharmaceutical company that develops, produces, and distributes a range of pharmaceutical products, primarily generating revenue through the sale of these products to healthcare providers and consumers.

Business. Pyridam Farma Tbk PT (PYFA.JK) is an Indonesian pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm is headquartered in Indonesia and primarily listed on the Indonesia Stock Exchange (IDX). Specific details regarding its operating segments and geographic revenue mix are not disclosed.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-49,5 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning PYFA.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to PYFA.JK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Pyridam Farma Tbk PT (PYFA.JK) is an Indonesian pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm is headquartered in Indonesia and primarily listed on the Indonesia Stock Exchange (IDX). Specific details regarding its operating segments and geographic revenue mix are not disclosed.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    The company's capital structure is highly leveraged, with a debt-to-equity ratio of 6.31, indicating a significant reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 1.24, suggesting limited short-term liquidity cushion. The company's price-to-book ratio of 3.46 implies that the market values the company at a premium to its book value, but this is not supported by positive earnings or cash flow. Free cash flow is negative at -256.15 billion IDR, and operating cash flow is also negative at -364.28 billion IDR, indicating ongoing cash burn.

    Profitability metrics are weak, with a return on equity of -0.495 and a return on assets of -0.0561, both significantly below industry norms. The company reported a net loss of 379.67 billion IDR and an operating loss of 217.20 billion IDR, reflecting poor operational performance. Gross profit of 583.14 billion IDR is insufficient to cover operating expenses, contributing to the net loss.

    Geographic and segment exposure is not explicitly detailed in the available data, but the company operates primarily in Indonesia. Revenue concentration in a single market increases exposure to local economic and regulatory risks. The absence of disclosed international operations or segment breakdowns limits visibility into diversification strategies.

    Growth trajectory is negative, with no clear indication of improvement in the near term. The company's operating income and net income are both in negative territory, and there is no evidence of a turnaround in the current fiscal year. The lack of positive cash flow and the high debt burden suggest that the company may face challenges in sustaining operations without external financing.

    Risk factors include liquidity constraints and the potential for dilution, although the latter is currently assessed as low. The company's negative net cash position after subtracting total debt is a key flag, indicating a high risk of insolvency if cash flow does not improve. The absence of a clear path to profitability or debt reduction increases the risk profile.

    Recent events include the publication of the latest financial results, which show continued losses and negative cash flow. No significant corporate actions or strategic initiatives have been disclosed in the available data. The company's financial health remains a concern, with no immediate signs of improvement in its operational or financial performance.

    Key takeaways
    • Pyridam Farma Tbk PT is highly leveraged with a debt-to-equity ratio of 6.31, indicating a significant reliance on debt financing.
    • The company is unprofitable, with a return on equity of -0.495 and a return on assets of -0.0561.
    • Free cash flow and operating cash flow are both negative, indicating ongoing cash burn and liquidity constraints.
    • The company's liquidity position is assessed as medium, with a current ratio of 1.24.
    • The company's negative net cash position after subtracting total debt is a key flag, indicating a high risk of insolvency.
    • There is no clear indication of a turnaround in the near term, with continued losses and negative cash flow.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $242,00
    Market cap
    $2.65T
    Enterprise value
    $7.49T
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    3.5x
    P / Tangible book
    3.5x
    Tangible book
    $766.99B
    Net cash
    -$4.84T
    Current ratio
    1.2
    Debt / equity
    6.3
    ROA
    -5.6%
    ROE
    -49.5%
    Cash conversion
    96.0%
    CapEx / revenue
    -6.1%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-7,9 %Below median
    Net Margin-13,8 %Bottom quartile
    ROE-49,5 %Bottom quartile
    Capex / Rev-6,1 %Below median
    D/E6,31Bottom quartile
    Cash Conv0,96Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    Source documents
    • Pyridam Farma Tbk PT Market data — financials · 2026-05-29

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    PYFA.JKCanonical
    IDX (Jakarta) · IDR

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage